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TRYPTOPHAN DEPLETION BY INDOLAMINE 2,3-DIOXYGENASE (IDO) 
CONTRIBUTES TO MEDIAL IMMUNOPRIVILEGE IN GRAFT 
ARTERIOSCLEROSIS.  
Amanda M. Silverio, Madison C. Cuffy, and George Tellides. Interdepartmental Program 
in Vascular Biology and Transplantation and the Departments of Surgery and 
Immunobiology, Yale University, School of Medicine, New Haven, CT. 
Introduction: Since blood vessels and their endothelial lining are major stimulators and 
targets of the graft rejection response, the study of the differential immune properties of 
vascular cells is needed for the proper application of human vessels in the transplant 
setting. Experimental models of atherosclerosis and graft arteriosclerosis show leukocytes 
selectively infiltrating the intima and adventitia while sparing the media. We explored the 
role of vascular smooth muscle cells (VSMCs) in mediating the observed 
immunosuppression and attributed it to the expression of indoleamine 2,3-dioxygenase 
(IDO) by VSMCs. IDO, in response to interferon-gamma (IFN-γ) signaling, catalyzes the 
first and rate-limiting step in the oxidative catabolism of tryptophan, an essential amino 
acid, and generates kynurenine metabolites. We further investigated the role of IDO in 
vascular immune regulation using both in vivo and in vitro studies.  
Methods: Segments of human coronary arteries from explanted hearts of cadaveric organ 
donors or cardiac transplant recipients were interposed into the infrarenal aortae of 
SCID/beige mice and harvested after five weeks for histologic analysis. RT-PCR 
reactions were prepared with pre-developed assay reagents for IDO, tryptophanyl-tRNA 
synthetase (WRS), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The 
expression level of each target was normalized to that of GAPDH. Co-culture 
experiments were performed by placing 2x105 endothelial cells (ECs) or VSMCs along 
with CFSE-labeled CD4+ T-cells in 24-well plates and treating with IFN-γ at 100 ng/mL 
for 3 days. The cultures were maintained in 5% CO2 at 37ºC for up to 9 days. T-cell 
proliferation was assessed by fluorescence-activated cell sorting (FACS) analysis of 
CFSE dilution after counterstaining with PE-labeled mouse anti-human CD4 antibody. 
Interleukin-2 (IL-2) levels were measured in the supernatants by enzyme-linked 
immunosorbent assay (ELISA).  
Results: Vessel grafts showed that medial sparing by allogeneic T-cells is associated 
with IDO expression by VSMCs. Exposure to the T-cell-derived cytokine, IFN-γ, led to 
100-fold greater expression of IDO mRNA in graft VSMCs than in ECs or CD4+ T-cells 
(2.00, 0.02, and undetectable IDO/GAPDH mRNA ratios, respectively). An 
immunoregulatory effect was shown when IFN-γ-treated VSMCs decreased CD4+ T-cell 
proliferation and IL-2 production (levels decreased by 98% and 90%, respectively), and 
addition of the IDO inhibitor, 1-methyl-tryptophan, led to a reversal of the inhibition. 
Inhibition was not seen with ECs or untreated VSMCs. CD4+ T-cell anergy was 
replicated by tryptophan depletion, but not by the addition of tryptophan metabolites: 
kynurenine, 3-hydroxykynurenine, and 3-hydroxyanthranilic acid. Tryptophan 
supplementation rescued T-cell proliferation in a dose-dependent fashion. 
Conclusions: We confirmed that vascular cells, namely VSMCs, could regulate adaptive 
immune responses by preferentially expressing IDO to inhibit CD4+ T-cell activation and 
clonal expansion. We also characterized IDO regulation of T-cells in the medial wall by 
showing that the depletion of tryptophan in the microenvironment inhibited CD4+ T-cell 
proliferation. Considering that the immune system relies on tryptophan regulation as a 
method to selectively modulate T-cell infiltration in graft vessel walls, the expression of 
IDO and the availability of tryptophan serve as potential therapeutic targets in the 
management of graft arteriosclerosis. 
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Introduction 
Inflammation plays a necessary role in coronary artery disease and atherosclerosis 
in which leukocytes and their effector molecules induce the remodeling of and 
progression of atheromata in blood vessel walls. Acute activation of inflammation can 
elicit acute coronary syndromes1, while an accelerated form of atherosclerosis may occur 
within months to years in transplanted hearts termed graft arteriosclerosis2. Experimental 
models of graft arteriosclerosis have shown that the inflammatory response in the arterial 
wall is not uniform. Leukocytes, namely T-cells and macrophages, selectively infiltrate 
the intimal and adventitial layers while sparing the medial layer3-5. The precise 
mechanisms explaining this differential immune response have yet to be elucidated, 
although a physical barrier hypothesis has been set forth. This is based on viral studies 
revealing the media as an immunoprivileged site in which the elastic laminae are thought 
to prevent leukocyte migration between layers6. We extend the concept of medial 
immunoprivilege to include an active role for vascular smooth muscle cells (VSMCs) in 
coordinating with the adaptive immune system to regulate inflammation in the blood 
vessel wall.  
 To investigate if the differential immune response in graft arteriosclerosis results 
from an anti-inflammatory factor produced by VSMCs, we explored the protein 
expression of VSMCs both in vivo and in vitro and hypothesized a leading role for 
indoleamine 2,3-dioxygenase (IDO). IDO, in response to interferon-gamma (IFN-γ) 
signaling, catalyzes the first and rate-limiting step in the oxidative catabolism of 
tryptophan, an essential amino acid, and generates kynurenine metabolites (Figure 1). 
IDO is an intracellular enzyme originally identified in rabbit intestine by Hayaishi et al. 
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in the 1960’s but has been found to be expressed in several tissues of the human body. 
Within the cardiovascular system, it has been recognized as a marker of the inflammatory 
response associated with atherosclerosis7, 8. However, it was historically studied for its 
ability to inhibit the proliferation of facultative intracellular pathogens and tumor cells 
through consumption of the essential amino acid, tryptophan9. And within the past twenty 
years, IDO has been given a more specialized function in immune regulation as it has 
been shown to suppress T-cell responses in experimental models of mammalian 
pregnancy, tumor resistance, autoimmune diseases, and transplant rejection10 (Figure 2). 
Antimicrobial Theory 
The depletion of tryptophan in the local microenvironment represents a simple but 
effective method for control of rapidly dividing microbial pathogens that are dependent 
on exogenous tryptophan for survival (i.e. auxotrophs that are either intracellular or else 
live in intimate association with a host cell). Examples include Chlamydia pneumoniae11, 
Toxoplasma gondii12, 13, cytomegalovirus14, herpes simplex virus15, and certain bacteria 
such as group B streptococci16 and mycobacteria17. Soon after its discovery, IDO was 
given a role within the innate host defense against these types of infections. As 
leukocytes and lymphocytes accumulate at the site of infection and release interferons 
into the inflammatory milieu, IDO is triggered to deplete the least available and therefore 
most important essential amino acid for the growth of susceptible pathogens18, 19. The 
effect of IDO is found to be due specifically to its ability to deplete tryptophan because 
tryptophan supplementation restores pathogen replication. 
While the antimicrobial action of IDO has been largely elucidated, the role of 
IDO in acquired immunity is still advancing and evolving.  
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Inhibition with 1-Methyl-Tryptophan (1-MT) 
Multiple trials showing inhibition of IDO with the 1-methyl analogue of 
tryptophan20-23 have enabled the advancement of IDO in the context of immune 
regulation. Landmark studies utilized 1-methyl-tryptophan (1-MT) as a specific IDO 
inhibitor to analyze IDO as an immunosuppressor in experimental animal models of 
allogeneic pregnancy and tumor immunity.  
Suppression of Maternal Anti-Fetal Immunity During Pregnancy  
It is well known that the survival of the genetically disparate, allogeneic 
mammalian fetus clearly contradicts the laws of tissue transplantation. Pioneering work 
by Munn and Mellor in the 1990’s attempted to elucidate the nature of this interaction by 
extending the function of IDO to include T-cell regulation in vivo. Munn and Mellor 
showed that the expression of IDO by placental cells prevented maternal T-cells from 
activating lethal anti-fetal immune responses24, 25. Blocking the action of IDO with 
administration of 1-MT during murine pregnancy enabled maternal T-cells to provoke 
fetal allograft rejection. Therefore, these studies gave direct evidence to suggest that IDO 
could be expressed by certain cells in vivo to suppress unwanted T-cell responses within a 
variety of environments in the human body19, 26-28. By depleting tryptophan in the local 
microenvironment, not only microbes but also T-cells were now shown to be susceptible 
to cells expressing IDO. This theory explaining T-cell inhibition in fetal tissues naturally 
extended to the critical arenas of tumor immunity and tissue allograft rejection.  
Prevention of T-cell Responses In Vitro 
To explain how cells expressing abnormal or allogeneic antigens could escape 
detection by the immune system, we first describe the multiple effects on T-cell 
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responses by IDO including (1) inhibition of T-cell proliferation; (2) promotion of T-cell 
apoptosis; (3) induction of T-cell ignorance, anergy, or deviation; and (4) generation of 
regulatory T-cells (Figure 3).  
Another landmark study by Munn et al. showed that differentiated monocytes 
acquire the ability to suppress T-cell proliferation in vitro via rapid and selective 
degradation of tryptophan by IDO20. T-cells activated under tryptophan-deficient 
conditions were able to enter the cell cycle but halted at the mid-G1 arrest point, not only 
preventing T-cell proliferation but also making them susceptible to death via apoptosis. 
T-cells were able to continue with the cell cycle and escape apoptosis only if 
supplemented with tryptophan and re-challenged by presentation of antigenic stimuli29.  
IDO+ dendritic cells could also be readily detected in vivo, which suggests that 
these cells may constitute a regulatory subset of antigen presenting cells (APCs) in 
humans19, 30, 31. The model of APCs as natural adjuvants that promote the immune 
response has now been modified after realizing the same cells that hold a critical role in 
the immune response must also be involved in tolerance to self-antigens and maintenance 
of T-cell homeostasis. In fact, IDO-expressing human dendritic cells have been found to 
drive naive, allogeneic CD4+ T-cells to differentiate into CD4+ CD25+ CTLA4+ Foxp3+ 
regulatory T-cells32, 33. It is thought that the generation of kynurenine metabolites by IDO 
drives this process of differentiation for the induction of peripheral tolerance. 
Inhibition of T-cell-mediated Responses to Tumor-Associated Antigens 
In the normal physiologic state, IDO is important in maintaining an environment 
that limits damage to tissues due to an overactive immune system. However, by 
promoting immune suppression, IDO can facilitate the survival and growth of tumor cells 
  5 
expressing abnormal antigens that would be readily recognized as foreign. Most human 
tumors have been found to constitutively express IDO, resulting in tumor immunity from 
an acquired state of tolerance. Examples include acute myeloid leukemia34 and other 
hematologic malignancies35, 36, uveal melanoma37, 38, cutaneous melanoma39, 40, 
endometrial adenocarcinoma41, 42, pancreatic ductal adenocarcinoma43, and prostate 
adenocarcinoma44. Therefore, strategies to block IDO have been suggested to enhance the 
effectiveness of cancer chemotherapy. 
With significant side effects limiting the full application of chemotherapeutics, 
any agent that could more specifically interfere with tumoral immune tolerance would be 
of great use in treating and even preventing cancer. Preclinical studies have shown that 
coadministration of 1-MT increases tumor responses to multiple treatments in 
leukemia/lymphoma36, melanoma, and fibrosarcoma models45-48. This is based on the 
premise that inhibiting IDO reverses the mechanism of immunosuppression and enhances 
anti-tumor immunity. The promising results have encouraged the clinical translation of 
IDO inhibitors49, the first of which entered phase I clinical trials in the fall of 2007.  
IFN-γ for the Induction of IDO 
On the other end of the spectrum, IFN-γ, generally known to be a pro-
inflammatory mediator, was being noted for its ability to induce the expression of IDO in 
several tissues50. IFN-γ is an important effector molecule released by antigen-specific T-
helper type 1 cells in acquired immunity. In the setting of immune regulation, IFN-γ was 
shown to induce IDO expression in peripheral blood mononuclear cells (PBMCs), 
monocyte-derived macrophages, and dendritic cells but not in lymphocytes11. In fact, 
IFN-γ is the most effective cytokine used for in vitro IDO induction in human cells51. An 
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in vivo model has also confirmed the ability of IFN-γ to induce IDO activity. IDO was 
dramatically induced in allografted tumor cells undergoing rejection, which was 
attributed to IFN-γ since antibody to IFN-γ completely neutralized the inducer activity22, 
52. It was proposed that IFN-γ was released through the interaction of allografted tumor 
cells with infiltrating leukocytes. Therefore, IDO and IFN-γ constitute a feedback loop 
for T-cell activation, differentiation, and regulation by antigen-presenting cells (Figure 
4).  
Ability of IFN-γ and IDO to Protect from Autoimmunity 
Since IDO is now emerging as a key player in multiple inflammatory conditions, 
proper IDO expression is thought to be critical in suppressing undesirable T-cell 
responses to self-antigens. The IFN-γ-IDO pathway can indeed serve as a negative 
feedback loop for T-helper type 1 cells, which have been implicated in a number of 
autoimmune diseases. In experimental models of autoimmunity, IFN-γ-induced 
expression of IDO has invariably been found to affect disease course profoundly as it 
drives the terminal differentiation and death of T-cells19. IDO has been shown to mediate 
the immunosuppression associated with graft-versus-host disease53, prevent development 
of Type 1 diabetes in streptozotocin-treated54 and non-obese diabetic (NOD) mice55-57, 
modulate autoreactive nephritogenic T-cell clones58, and protect thyroid glands from 
autoimmune attack in NOD-H2(h4) mice59. A key role for IDO in the regulation of the 
immune response cannot be underestimated as inhibition or impairment of IDO 
production exacerbates the development of organ-specific autoimmunity. In a variety of 
animal studies, inhibition with 1-MT worsened symptoms of encephalomyelitis60, 
primary biliary cirrhosis61, and colitis62. This kind of immunological intervention, 
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although not yet studied for systemic autoimmune reactivity, serves as a launching point 
for designing effective treatments for specific autoimmune diseases.  
Therapeutic Considerations 
Genetic manipulation of IDO activity has been recently studied as a therapeutic 
option in suppressing undesirable T-cell responses. Overexpression of IDO in IDO-
transfected cell lines results in suppression of antigen-specific T-cell responses in vitro63, 
and IDO overexpression in mouse tumor-cell lines renders them resistant to immune 
rejection in vivo64. Adenoviral-mediated IDO gene transfer into pancreatic islet cells 
prolongs their survival in allogeneic hosts65, as does transfection with IDO to protect 
allogeneic skin grafts66, corneal67, liver68, 69, and lung70, 71 transplants from rejection. 
These are just a few examples of how IDO overexpression represents a new 
immunomodulatory strategy for treatment of T-cell-mediated autoimmune diseases as 
well as allograft rejection. 
  8 
Statement of Purpose and Hypothesis 
The aims of this study were to determine whether local expression of an 
immunomodulatory molecule, namely IDO, was responsible for the differential immune 
response in blood vessel walls and to characterize the mechanism further as a potential 
target in the management of graft arteriosclerosis and transplant immunity in general. We 
look to IDO as a major player in allograft survival since it has already been shown to act 
as a local immunosuppressive molecule in a variety of contexts. Because of the critical 
role of endothelial cells in graft rejection, we intend to investigate the role of IDO 
expression by vascular cells and its consequence on immunoregulation.  
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Methods 
Division of Labor 
 Members of Dr. George Tellides’ laboratory team, specifically Yinong Wang and 
Madison Cuffy, prepared all aspects of the in vivo studies. Technical staff assisted me 
with vascular smooth muscle cell and endothelial cell isolation, high performance liquid 
chromatography (HPLC), and statistical analysis. I performed all other activities related 
to the studies including cell culture maintenance, media preparation, IFN-γ treatment, and 
CD4+ T-cell isolation and staining. I also carried out all in vitro studies including 
quantitative PCR, cell co-culture and transwell assays. 
Artery Grafting and In Vivo Treatments (Performed by Yinong Wang and Madison Cuffy) 
 Segments of human coronary arteries from explanted hearts of cadaveric organ 
donors or cardiac transplant recipients were interposed into the infrarenal aortae of severe 
combined immunodeficient (SCID)/beige mice (Taconic) using an end-to-end 
microsurgical anastomotic technique. At 1 week post-operatively, a subset of animals 
received intraperitoneal injections of 3x108 human peripheral blood mononuclear cells 
(PBMCs), which were obtained from healthy volunteers by apheresis and isolated by 
density centrifugation. For IDO inhibition experiments, we treated pairs of SCID/beige 
mice that received adjacent segments of human coronary arteries and the same allogeneic 
human PBMCs with either a placebo or 1-MT. Mice received either placebo pellets or 
200 mg 1-methyl-DL-tryptophan pellets subcutaneously for 1 to 4 weeks (Innovative 
Research). Human subject protocols were approved by the Yale Human Investigations 
Committee and the New England Organ Bank and animal procedure protocols were 
approved by the Yale Animal Care and Use Committee. 
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Graft Analysis (Performed by Yinong Wang and Madison Cuffy) 
 Artery grafts were harvested at 5 weeks post-operatively and analyzed by 
immunohistochemistry using mouse anti-human CD45RO, α-SMA (DAKO), and IDO 
antibodies (Chemicon). Binding of secondary antibody (Jackson ImmunoResearch) was 
detected with peroxidase/3-amino-ethyl carbazole kits (Vector). Cell counting of nuclei 
surrounded by positive immunostaining was performed under high magnification and 
averaged from 5 cross-sections for each graft. Intima, media, and adventitia areas were 
measured by computer-assisted microscopy and image software. 
Cell Isolation and Culture 
 Human umbilical vein endothelial cells (HUVECs) were isolated by enzymatic 
harvesting from umbilical cord veins and serially cultured in M199 medium (containing 
L-tryptophan at 49 µmol/L) supplemented with 20% fetal bovine serum (FBS), 2 mmol/L 
L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin (all from Invitrogen), 50 
µg/ml fibroblast growth factor-1 (Collaborative Research), and 100 µg/ml porcine 
intestinal heparin (Sigma-Aldrich). Human aortic or coronary artery vascular smooth 
muscle cells (VSMCs) were isolated by explant outgrowth and serially cultured in M199 
medium supplemented with 20% FBS, L-glutamine, and antibiotics. Cell cultures were 
used at passage 3 to 4. 
 Human CD4+ T-cells were isolated by positive selection from a sample of 3x108 
PBMCs using Dynabeads (Dynal Biotech) and further purified by depleting recently 
activated T-cells and naïve T-cells with anti-mouse IgG Dynabeads and mouse anti-
human HLA-DR and CD45RA antibodies (Pharmingen) at 10 µg/ml. Isolated cells were 
>95% CD45RO+/CD4+ activated and memory T-cells by fluorescence-activated cell 
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sorting (FACS) analysis. T-cells were cultured in RPMI 1640 medium (containing L-
tryptophan at 24.5 µmol/L) supplemented with 10% FBS, L-glutamine, and antibiotics. 
IFN-γ Treatment of HUVECs, VSMCs, and CD4+ T-cells  
HUVECs and VSMCs were treated with IFN-γ for 6 hours in 6-well plates 
containing M199 supplemented with 20% FBS. CD4+ T-cells were treated with IFN-γ 
for 6 hours in 6-well plates containing RPMI 1640 supplemented with 10% FBS. For 
HUVECs and VSMCs, 2x105 cells were present in each well at the start of the 
experiment. For CD4+ T-cells, 2x106 cells were present in each well. 
Quantitative PCR 
Total RNA was isolated from IFN-γ-treated cells and DNase-treated using 
NucleoSpin RNA II kits (Clontech Laboratories). Bulk reverse transcription with random 
hexamer primers was performed according to the Multiscribe RT system protocol 
(Applied Biosystems). RT-PCR reactions were prepared with TaqMan 2x PCR Master 
Mix and pre-developed assay reagents for glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), IDO, and tryptophanyl tRNA-synthetase (WRS) (Applied Biosystems). An 
iCycler and its system interface software (Bio-Rad Laboratories) were used to run 
samples and analyze data. All cDNA samples were run in duplicate. A DNase-treated 
RNA sample processed without the reverse transcriptase enzyme was used as the 
negative control. The expression level of each target was normalized to that of GAPDH. 
Cell Co-Culture and Transwell Assays 
 Co-culture experiments were performed by placing 2x105 ECs or VSMCs in 
gelatin-coated wells of 24-well culture plates and where indicated treated with IFN-γ 
(Biosource International) at 100 ng/ml for 3 days, washed in medium, and confirmed to 
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express class II MHC antigens by FACS analysis. T-cells were labeled with 250 nM 
CFSE (Molecular Probes) for 20 minutes, and 1x106 CD45RO+/CD4+ T-cells in 1 ml of 
supplemented RPMI 1640 medium was added to wells containing vascular cells. The 
cultures were maintained in 5% CO2 at 37 ºC for up to 9 days.  
In transwell experiments (Figure 5), 2x105 ECs or VSMCs were placed in an 
additional 0.5 ml of medium within 0.4-µm pore-size membrane inserts (Becton 
Dickinson) suspended above the cell co-cultures. In certain experiments, 1-methyl-D-
tryptophan (Sigma-Aldrich), adjusted to pH of 7.4, was added at 200 µmol/L. T-cell 
proliferation was assessed by FACS (Becton Dickinson) analysis of CFSE dilution after 
counterstaining with PE-labeled mouse anti-human CD4 antibody (Immunotech). IL-2 
levels were measured in supernatants by enzyme-linked immunosorbent assay (ELISA, 
eBioscience) according to the manufacturer’s instructions. 
 Certain co-culture experiments were performed in Advanced RPMI 1640 medium 
(an enriched formulation that enables cell growth in low serum concentrations) that was 
custom-ordered tryptophan-free (Invitrogen) and supplemented with 0.5% FBS and 
different doses of L-tryptophan (Sigma-Aldrich) (Figure 6). Alternatively, the co-cultures 
were maintained in conventional RPMI 1640 medium supplemented with 10% FBS and 
different doses of L-kynurenine, 3-hydroxy-DL-kynurenine, or 3-hydroxyanthranilic acid 
(Sigma-Aldrich). 
High Performance Liquid Chromatography (HPLC)   
 Tryptophan and kynurenine concentrations were determined by high performance 
liquid chromatography (HPLC). Tryptophan was monitored by its native fluorescence at 
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285 nm excitation and 360 nm emission wavelengths, and kynurenine was detected by 
UV-absorption at 365 nm wavelength in the same chromatographic run. 
Statistical Analyses 
 Student’s t-test and one-way ANOVA were performed using Prism (GraphPad 
Software). Differences with p<0.05 were considered to indicate statistical significance. 
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Results 
Medial Sparing by Allogeneic T-cells is Associated with VSMC Expression of IDO  
(As Shown by Yinong Wang and Madison Cuffy) 
We demonstrated VSMC-mediated immunosuppression in vivo using transplanted 
vessels in severe combined immunodeficient (SCID) mice reconstituted with allogeneic 
human peripheral blood mononuclear cells (PBMCs) as representative models of graft 
arteriosclerosis. The inflammation observed in response to allogeneic antigens was 
characterized by T-cell invasion of the intimal and adventitial layers with relative sparing 
of the media (Figure 7A). Manual cell counts of graft CD45RO+ T-cells showed a 
statistically significant 100-fold greater density of T-cells in the adventitia of 
reconstituted mice versus controls, and a statistically significant 2000-fold greater density 
of T-cells in the intima of reconstituted mice versus controls (Figure 7D). There was no 
significant difference observed in the number of T-cells within the medial layer of the 
experimental group versus control group (Figure 7D). Since inflammation in the media 
was insignificant compared to controls (Figure 7E), loss of VSMCs and decrease in 
medial width were also insignificant as shown by consistent staining of α-smooth muscle 
actin (α-SMA) (Figure 7B). We then proved medial expression of IDO with IDO+ 
staining after immune reconstitution and stimulation (Figure 7C). Data are n=6 and 
*p<0.05 when comparing samples from the experimental group receiving PBMC 
reconstitution versus samples from the control group without reconstitution. 
In Vitro Confirmation of IFN-γ-Inducible Expression of IDO by VSMCs 
Using reverse transcription polymerase chain reaction (RT-PCR), we confirmed 
the expression of IDO by showing the difference in RNA levels within VSMCs versus 
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endothelial cells (ECs) and CD4+ T-cells. Exposure to the T-cell-derived cytokine, IFN-
γ, resulted in at most 100-fold greater expression of IDO in VSMCs as compared to ECs 
and CD4+ T-cells (2.00, 0.02, and undetectable IDO/GAPDH mRNA ratios, 
respectively). We also observed a dose-dependent response to IFN-γ (Figure 8). Data 
represent single values and are representative of three independent experiments. 
Greater induction of IDO expression in VSMCs versus ECs correlated with orders 
of magnitude greater IDO activity as shown by time and dose response to IFN-γ for 
tryptophan depletion, kynurenine production, and the ratio of metabolite to precursor 
(Figure 9). Data represent single values and are representative of three independent 
experiments. 
IFN-γ-Treated VSMCs Suppress CD4+ T-cell Activation by Allogeneic ECs 
We observed a difference in ability of cultured vascular cells to activate 
allogeneic CD4+ T-cells within a co-culture system. ECs treated with IFN-γ expressed 
major histocompatibility complex (MHC) class II molecules, thereby enabling them to 
activate allogeneic CD4+ T-cells and generate an increase from 0.33% to 6.04% of T-
cells proliferating (Figure 10A). VSMCs treated with IFN-γ were also found to express 
MHC class II molecules but were unable to induce CD4+ T cell proliferation, which 
remained low at 0.15% (Figure 10A).  
We also set out to measure interleukin-2 (IL-2) levels since IL-2 is a cytokine 
responsible for stimulating T-cell proliferation. IFN-γ-treated ECs, but not VSMCs, 
stimulated IL-2 production by CD4+ T-cells after 2 days of co-culture (Figure 10B). The 
lack of IL-2 secretion and T-cell proliferation by IFN-γ-treated VSMCs was associated 
with greater tryptophan depletion and kynurenine production than similarly treated ECs 
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(Figure 10C-E). Data are means±SEM; n=6 for ELISA and n=3 for HPLC; *p<0.001 all 
vs. EC- control, †p<0.01 VSMC+ vs. EC+, and §p<0.001 VSMC+ vs. VSMC-. 
Using a transwell assay design, we showed that activated VSMCs can suppress 
the CD4+ T-cell activation by MHC class II+ ECs. Compared to our negative control of 
MHC class II- ECs leading to minimal proliferation (0.19%), our positive control of 
MHC class II+ ECs showed a population of proliferating CD4+ T-cells of almost 7%. 
Addition of unactivated VSMCs to the top well did not have a significant effect on the 
amount of T-cell proliferation. However, adding activated VSMCs led to a significant 
drop in proliferating T-cell numbers, from 6.75% to 1.39% (Figure 11A,B). We also 
measured a concurrent drop in IL-2 levels from 23 to 6 pg/ml (Figure 11C), as well as a 
significant increase in the kynurenine to tryptophan ratio from 0.08 to 0.52 (Figure 11D) 
after addition of IFN-γ-treated VSMCs. Data are means±SEM; n=5; *p<0.001 all vs. EC- 
control, †p<0.001 VSMC+ vs. EC+, and §p<0.001 VSMC+ vs. VSMC-. 
Inhibition of IDO with 1-MT Increases Medial T-cell Infiltration and VSMC Loss  
(As Shown by Yinong Wang and Madison Cuffy) 
 1-methyl-tryptophan (1-MT) was used to specifically inhibit IDO and to show 
that its activity is responsible for medial immunoprivilege. When compared to a placebo, 
1-MT did not affect T-cell numbers in SCID/beige mice reconstituted with PBMCs 
(6.8±1.7% versus 5.0±0.9% human CD3+ cells/mouse CD45+ cells, respectively, 
p=0.4790). However, the presence of 1-MT did increase T-cell infiltration into the medial 
layer and decreased the expression of the VSMC marker, α-smooth muscle actin (α-
SMA), indicating VSMC loss (Figure 12A,B). VSMC loss did not occur in 1-MT-treated 
recipients in the absence of PBMCs (Figure 12B insets). Manual cell counts supported a 
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significant two-fold increase in T-cell numbers within the medial layer, as well as a 
significant loss of almost half of VSMCs after 1-MT treatment. We also observed a 
higher density of T-cells in the intima after 1-MT treatment, but the increase was more 
modest than that of medial infiltration (26% vs. 83% increase, respectively) and did not 
reach statistical significance. Although the immunosuppressive activity of IDO was 
shown to be altered by 1-MT, the presence of 1-MT did not significantly alter IDO 
expression by VSMCs (Figure 12C). Data are n=6 and p<0.01 when comparing the 
experimental group receiving 1-MT versus the control group with placebo. 
Inhibition of IDO with 1-MT Reverses the VSMC-Mediated Suppressor Activity on T-cells 
 To support our in vivo findings with 1-MT, we added 1-MT to our transwell 
system to show that it can reverse the immunosuppressive effect of VSMCs by 
specifically targeting IDO activity. Addition of 1-MT alone did not affect the 
proliferation of CD4+ T-cells co-cultured with IFN-γ-treated, allogeneic ECs (8.21% vs. 
8.18%, respectively) (Figure 13A). Similarly, there was no effect of 1-MT on T-cell 
proliferation when added with untreated VSMCs to CD4+ T-cells co-cultured with IFN-
γ-treated, allogeneic ECs (Figure 13B). However, addition of 1-MT with activated 
VSMCs thwarted the expected decrease in T-cell proliferation from VSMC expression of 
IDO (8.38% vs. 2.34%, respectively) (Figure 13A,B). The presence of 1-MT also 
reversed the IFN-γ-dependent, VSMC-mediated inhibition of IL-2 production by CD4+ 
T-cells stimulated by MHC class II+ ECs (Figure 13C), as well as prevented the 
depletion of tryptophan and the production of kynurenine by activated VSMCs (Figure 
13D). To prove that 1-MT acts to inhibit IDO specifically without stimulating T-cell 
proliferation itself, we showed that addition of 1-MT without MHC class II+ ECs fails to 
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increase the population of proliferating T-cells (Figure 14A). Data are means±SEM; n=5 
for B-D, n=8 for E; *p<0.01 all vs. EC- control, †p<0.01 VSMC+ vs. EC+, §p<0.01 
VSMC+ vs. VSMC-, and #p<0.01 1-MT vs. vehicle. 
IDO Immunosuppression is Mediated by Tryptophan Depletion, Not by Toxic Metabolites 
 We set out to further characterize IDO using the co-culture system to examine if 
tryptophan depletion or metabolite production was more important in mediating 
immunosuppression. It was important to show first that addition of tryptophan cannot, by 
itself, stimulate T-cell proliferation since MHC class II+ ECs are required for T-cell 
activation (Figure 14B).  
We then demonstrated that CD4+ T-cells cannot be activated by MHC class II+ 
ECs in the presence of a minimal tryptophan concentration of <0.5 µmol/L (Figure 14C). 
This concentration is similar to the reduced level of tryptophan observed in co-cultures 
with IFN-γ-treated VSMCs. However, supplementation of this tryptophan-deficient 
environment with L-tryptophan resulted in a significant increase in CD4+ T-cell 
proliferation (Figure 14C) and IL-2 production (Figure 14D) in a dose-dependent fashion.  
In contrast, addition of three-fold higher levels of kynurenine metabolites (30 
µmol/L) than that produced by IFN-γ-treated VSMCs did not significantly affect T-cell 
clonal expansion (Figure 14E), nor did it significantly alter IL-2 production (Figure 14F). 
Data are means±SEM; n=6 for ELISA and n=3 for HPLC; *p<0.001 all vs. EC- control. 
In recent studies using the transwell system to demonstrate VSMC- and IDO-
mediated immunosuppression, tryptophan supplementation has been shown to rescue T-
cell proliferation after challenge with activated VSMCs (Figure 13E). This gives further 
evidence of IDO utilizing tryptophan starvation as a method of immune regulation. 
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Expression of WRS May Allow VSMCs to Adapt to Lower Levels of Tryptophan  
To shed light on the susceptibility of different cell types to lower than normal 
levels of tryptophan, we looked for the expression of tryptophanyl-tRNA synthetase 
(WRS), an enzyme that is essential for tryptophan integration into proteins. RT-PCR 
showed a 20-fold greater expression by VSMCs as compared to ECs and CD4+ T-cells 
(9.19, 0.33, 0.84 IDO/GAPDH mRNA ratios, respectively) (Figure 15). Data represent 
single values and are representative of three independent experiments. 
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Discussion 
It is important to note first that we consider medial immunoprivilege to be a 
relative phenomenon. There is definite evidence suggesting that inflammation can occur 
throughout the arterial wall and that medial necrosis is sometimes present in robust acute 
rejection episodes72. Similarly, transmural infiltration and medial destruction is 
characteristic of certain vasculitides73, 74. Therefore, it is not surprising that the media is 
capable of recruiting leukocytes under certain conditions since a variety of cytokines 
have been found to induce vascular smooth muscle cells (VSMCs) to express many 
immunogenic and pro-inflammatory molecules75, 76. We propose that medial 
immunoprivilege becomes manifest when the dormant potential of IFN-γ inflammatory 
signaling becomes activated by reactive antigens of atherosclerosis and graft 
arteriosclerosis, which tip the balance over the susceptibility of the media to 
inflammation and act to modulate an overwhelming immune response.  
Activated VSMCs are Responsible for the Medial Sparing by CD4+ T-cells 
We promote the concept of medial immunoprivilege by defining an active role for 
VSMCs in regulating the inflammatory response within blood vessel walls. First, we used 
experimental animal models of graft arteriosclerosis to confirm medial sparing by T-cells 
after immune reconstitution and antigen challenge of severe combined immunodeficient 
(SCID)/beige mice with allogeneic peripheral blood mononuclear cells (PBMCs). The 
absence of infiltrating T-cells within the media was then associated with expression of 
indoleamine 2,3-dioxygenase (IDO). Considering that the immune system relies on 
tryptophan regulation as a method to target pathogens selectively9, we set out to prove 
that IDO also affects T-cells by a similar mechanism of tryptophan metabolism.  
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IFN-γ was used to initiate the feedback loop for T-cell activation since it is both 
secreted by T-cells and is the most effective cytokine for inducing IDO expression in 
vitro51. When an inflammatory stimulus is present, such as an allogeneic antigen, T-cells 
are specifically recruited to the area and release IFN-γ. In our proposed model of graft 
arteriosclerosis, ECs are the major stimulators and the initial targets of the graft rejection 
response since they are first to contact donor T-cells. Secretion of IFN-γ by recruited T-
cells stimulates MHC class II expression by ECs, thereby activating T-cells to proliferate 
in preparation for a coordinated immune attack. We propose that IFN-γ also stimulates 
nearby VSMCs to express IDO in order to regulate the immune response and suppress 
unwarranted T-cell responses.  
Our hypothesis was confirmed using in vitro assays to show that IFN-γ induced 
an overwhelmingly greater expression of IDO RNA by human VSMCs than in ECs or 
CD4+ T-cells. As expected, these results correlated with orders of magnitude greater IDO 
activity by IFN-γ-treated VSMCs as shown by a significant decrease in tryptophan levels, 
increase in kynurenine metabolites, and increase in the kynurenine to tryptophan ratio.  
We then demonstrated in transwell assays that IFN-γ-induced expression of IDO 
by VSMCs suppressed the CD4+ T-cell proliferation typically seen in response to MHC 
class II+ ECs. Without MHC class II expression by ECs, CD4+ T-cells did not receive 
the stimulus to proliferate even in the presence of VSMCs, with or without IFN-γ-
pretreatment and expression of IDO. This suggests that VSMCs lack a co-stimulatory 
molecule themselves and, along with the suppressive effects of IDO, act to down-regulate 
the immune response. 
Inhibition of CD4+ T-cell Proliferation is Specific to IDO Expression and Activity 
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To demonstrate that IDO is the main immunosuppressor and not a combination of 
multiple other proteins, we explored the use of 1-methyl-tryptophan (1-MT) since it is a 
known inhibitor of IDO both in vivo24 and in vitro20. It is unlikely that 1-MT has another 
target besides IDO as it does not induce abortion of allogeneic fetuses in IDO-knockout 
mice as occurs in IDO-expressing mice77. In our experimental animal models, we see that 
administration of 1-MT led to an increase in the presence of T-cells in the medial layer. 
We also detected a significant loss of VSMCs most likely due to the infiltration and 
destruction by T-cells. The possibility that VSMC loss was caused by nonspecific toxic 
effects of 1-MT was eliminated since the inhibitor had no effect on the artery grafts in the 
absence of immune reconstitution with allogeneic T-cells. Pharmacologic inhibition of 
IDO also had no effect on immune cell numbers as PBMC counts remained relatively 
constant even after administration of 1-MT. Furthermore, we show that expression of 
IDO is unchanged in the presence of 1-MT. It can therefore be demonstrated that IDO 
can be specifically inhibited in vivo without side effects confounding the expected 
alterations in immune response. 
We again confirmed our in vivo results using the transwell assay design to prove 
that specifically inhibiting IDO with 1-MT leads to the reversal of VSMC-mediated 
suppressor activity on CD4+ T-cells. Wells with semi-permeable membranes were used 
in order to show that it is not a cell-to-cell interaction but instead a soluble factor that is 
responsible for the inhibition of T-cell proliferation. As one recalls, IDO is an 
intracellular enzyme and therefore its mechanism of action is to alter the composition of 
essential nutrients within the local environment. VSMCs restricted to a semi-permeable 
membrane are not allowed to have contact with ECs and CD4+ T-cells on the other side 
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of the membrane; hence we observe any immunosuppressive effects owing to alterations 
in the microenvironment of cells. The reversal of effects seen after addition of 1-MT 
gives further proof of the key role of IDO in mediating immunosuppression through 
tryptophan metabolism. 
Tryptophan Starvation Mediates Suppression of T-cell Proliferation 
Separate theories have been proposed to explain how tryptophan catabolism 
facilitates tolerance. One theory argues that tryptophan breakdown suppresses T-cell 
proliferation by dramatically reducing the supply of this essential amino acid. The other 
theory postulates that the downstream metabolites of tryptophan catabolism are directly 
toxic and act to suppress T-cell proliferation through intracellular signalling78-80. A 
combination of both theories has been advocated by Frumento et al. who demonstrated 
that three tryptophan catabolites (i.e. kynurenine, picolinic acid, and quinolinic acid) 
were responsible for the inhibition of T- and NK-cell proliferation induced by IDO, their 
suppressive effect being potentiated by tryptophan depletion81.  
We characterized IDO’s regulation of immune cells in the medial wall by 
showing that tryptophan depletion, not build-up of toxic metabolites, is solely responsible 
for the inhibition of CD4+ T-cell proliferation. CD4+ T-cell anergy and decreased 
secretion of IL-2 were replicated by diminishing levels of tryptophan within the culture 
medium surrounding cells, but not by the addition of tryptophan metabolites: kynurenine, 
3-hydroxykynurenine, and 3-hydroxyanthranilic acid. This finding strengthens the 
historic model of IDO utilizing tryptophan depletion to fight off pathogens18, 19 and 
extends IDO’s capabilities to function within acquired immunity.  
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Since adding excess tryptophan reversed the antimicrobial effects of IDO, it 
should follow that our studies show tryptophan supplementation reversing the IDO-
mediated inhibition of CD4+ T-cells.  
Although tryptophan metabolites at reasonable levels did not demonstrate an 
effect on T-cell proliferation, future studies should look at the potential for kynurenines 
to induce T-cell apoptosis. We were able to measure the population of dividing cells but 
did not look for expression of caspases or changes in nuclear morphology to indicate 
active apoptotic signaling. Pro-apoptotic mechanisms should be investigated based on 
studies showing kynurenines as neuroactive molecules that cause neuronal death through 
a combination of necrosis and NMDA receptor-triggered apoptotic cascades19, 82-84. 
Within the field of immunology, recent work has provided evidence for an important role 
of kynurenines in IDO-mediated apoptosis of thymocytes and T-helper type 1 cells19, 85. 
Morita et al. have also shown that the tryptophan metabolite, 3-hydroxyanthranilic acid, 
induces apoptosis in monocyte-derived cells expressing IDO86.  
It would also be of interest to explore the capability of tryptophan deprivation or 
kynurenine production to induce T-cell tolerance or the generation of regulatory T-cells. 
Belladonna et al. were able to demonstrate IDO-mediated tolerogenesis in dendritic cells 
by inhibiting an adapter molecule required for activation87. They were also able to 
generate regulatory T-cells in a microenvironment with low tryptophan concentration and 
a mixture of kynurenines to protect mice in an experimental model of fulminant 
diabetes87. In models of transplant immunity, Bauer et al. showed that IDO-induced 
tryptophan metabolites suppressed the T-cell response thereby prolonging allograft 
survival in rats88. Therefore, there is evidence to suggest that kynurenines possess a 
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unique mechanism, other than inhibition of T-cell proliferation, to effectuate IDO 
immunosuppression. 
With both tryptophan depletion and toxic metabolites, the effects have been 
mainly shown in vitro. Precisely how either mechanism would function in vivo remains 
speculative. The degree of tryptophan depletion that is required to inhibit T-cell 
proliferation (<0.5 µmol/L from the 0.5% serum supplementation of tryptophan-deficient 
cell culture medium) is markedly lower than that normally found in the plasma (40-100 
µmol/L). However, we must consider that the microenvironment surrounding cells is not 
in equilibrium with the blood. Local concentrations of tryptophan may indeed vary 
markedly from that observed in the plasma.  
In the case of tryptophan metabolites, there have been studies reporting toxic 
effects to T-cells but with much higher concentrations (>100 µmol/L)78, 81 of tryptophan 
metabolites than the levels we measured from IDO activity in activated VSMCs both in 
vivo and in vitro (10 µmol/L). In fact, concentrations >100 µmol/L exceed the available 
amount of tryptophan precursor in the blood. This can be explained by considering that 
local concentrations of metabolites also vary markedly within microenvironments 
affected by IDO activity.  
VSMCs May Adapt to Lower Levels of Tryptophan by Optimizing Usage Efficiency 
In the setting of tryptophan starvation, T-cells are susceptible but VSMCs 
maintain normal morphology and function. There are a couple of possible reasons why 
VSMCs but not T-cells are able to compensate for the reduction in tryptophan, an 
essential amino acid. First, activated T-cells undergo massive clonal expansion thus 
requiring a higher rate of protein synthesis. Second, VSMCs but not CD4+ T-cells can be 
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induced by IFN-γ to express an adaptive enzyme called tryptophanyl-tRNA synthetase 
(WRS). WRS is essential for tryptophan incorporation into proteins, thereby allowing 
VSMCs to adapt to lower levels of tryptophan by increasing the efficiency of its use. 
Future work should include studies to determine the levels of charged tRNATrp versus 
uncharged tRNATrp in order to confirm WRS activity. 
Potential Therapeutic Targets 
Since we have expanded the function of IDO to include regulation of the adaptive 
immune response within blood vessel walls, the expression of IDO and the availability of 
tryptophan now serve as potential therapeutic targets for the advancement of transplant 
immunity. This is because blood vessels and their endothelial lining are major stimulators 
of the graft rejection response, and therefore any method to down-regulate this response 
specifically could conceivably lengthen allograft survival and eliminate the use of 
systemic immunosuppressive drugs.  
The concept of IDO overexpression is first discussed as it has been studied 
successfully both in vivo and in vitro within the past couple of years since our results 
were published. In animal transplantation models, adenovirus vector was used to transfer 
the IDO gene into donor organ cells. This technique effectively protected allogeneic skin 
grafts66, corneal67, liver68, 69, and lung70, 71 transplants from rejection. Work by Jalili et al. 
was done to determine whether local expression of IDO in bystander syngeneic 
fibroblasts could prevent immune response to allogeneic islet cells in vitro. After mouse 
fibroblasts were induced to express IDO by either IFN-γ treatment or transduction with 
adenoviral vector, the fibroblasts were able to inhibit the expected lymphocyte 
proliferation after stimulation with allogeneic antigen89.  
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We can apply the same approach with our model of vascular-mediated immune 
regulation to bring about organ-specific transplant immunity and to prevent graft 
arteriosclerosis, a major cause of graft rejection. Donor ECs could be made to 
overexpress IDO in order to modulate T-cell infiltration into graft vessel walls. Indeed, 
this approach holds much promise in defining a feasible method for promoting the proper 
application of human vessels in the transplant setting. 
Along the same lines of inducible IDO expression, we can take a step backwards 
and target the production and signaling of interferon-gamma (IFN-γ) within the artery 
wall. IFN-γ is secreted by T-helper type 1 cells, cytotoxic T-cells, dendritic cells and 
natural killer cells, so it is not surprising that it plays a major role in the adaptive immune 
system for its immunoregulatory, anti-viral, and anti-tumor properties90. Its importance in 
the pathogenesis of atherosclerosis has been well defined over the past twenty years. In 
addition to upregulating expression of both cell-surface and secreted proteins by 
endothelial cells91, IFN-γ is responsible for promoting antigen presentation of 
macrophages, adhesion and binding for leukocyte migration, and activation of antigen 
presenting cells to promote T-helper type 1 differentiation90. The therapeutic value of 
IFN-γ then comes from the potential to specifically target the immune response 
underlying graft arteriosclerosis and prevent unwanted vascular remodeling as occurs in 
graft rejection. 
There has yet to be a study on the manipulation of tryptophan levels as it affects 
allograft survival. One must consider that the concentration of any molecule is difficult to 
control in the local microenvironment, let alone systemically, since a tendency towards 
equilibrium will continue to alter concentration levels. In addition, extremely low levels 
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of tryptophan are required to suppress T-cell proliferation in vitro, making it virtually 
impossible to replicate in vivo without causing disseminated or even systemic side 
effects. We must also remember that IDO is expressed within a complex array of immune 
signaling. In the absence of stimuli for upregulation of adaptive responses (i.e. IFN-γ-
induced expression of tryptophanyl-tRNA synthetase), bystander cells may become 
susceptible to isolated tryptophan depletion. 
One anticipated problem to consider with these therapeutic suggestions is the 
quandary of cross-species applicability. Our findings in human VSMCs, ECs, and arteries 
may not necessarily apply to murine systems due to species differences in vascular cell 
interactions with T-cells. Although we confirm that MHC class II antigen-expressing 
human ECs can directly activate allogeneic CD4+ T-cells92, it has been shown that IFN-
γ-treated murine ECs cannot93. Conversely, we show that both IFN-γ-treated and 
untreated human VSMCs are incapable of activating allogeneic CD4+ T-cells. Murine 
VSMCs appear to be immunogenic and can activate T-cells to produce IFN-γ and 
mediate vasculitis94, 95. However, the recent success in translating the study of IDO 
inhibitors from experimental animal models to clinical trials49 holds much promise in the 
advanced application of our in vivo and in vitro findings. 
Another anticipated issue stems from the interesting discrepancy seen when 
comparing results from permanent gene targeting versus transient blocking experiments. 
The landmark study by Munn et al. offers a notable example. Inhibiting IDO with 1-MT 
removed the suppression on maternal murine T-cells, which subsequently provoked the 
abortion of allogeneic murine fetuses24. Surprisingly, knockout of the IDO gene to 
produce IDO-deficient mice did not lead to fetal allograft rejection. Allogeneic 
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pregnancies of IDO-deficient mice had similar outcomes to those of IDO-sufficient mice. 
What the knockout studies did show is that it is unlikely that 1-MT has another target 
besides IDO as it does not induce abortion of allogeneic fetuses in IDO-knockout mice as 
occurs in IDO-expressing mice77. The unexpected results from IDO-knockout mice imply 
that there are redundant and compensatory immunosuppressive mechanisms in the 
placenta and, although not necessary, IDO plays a key role in immune regulation. 
Future Directions 
IFN- γ, IDO, ECs, VSMCs, and CD4+ T-cells all function in the context of 
constantly evolving environments, heterogeneous timepoints, and convoluted arrays of 
immune signaling. It would be of interest to explore the role of other inflammatory 
cytokines like TGF-β. Preliminary studies of TGF-β in vascular models show that 
serologic neutralization of TGF-β does not relieve the suppressive effects of activated 
VSMCs in co-culture with T-cells96. Subsequent experiments should focus on identifying 
the downstream effector molecules of TGF-β as it applies to the inflammatory response 
in human blood vessels.  
In ongoing studies, we are looking for any differences in the proliferation and 
viability of bystander CD8+ T-cells versus our results with CD4+ T-cells in response to 
an IDO-induced tryptophan deficient environment. If there are any significant variations 
observed, then we would like to determine the mechanisms involved. Transwell assays 
should allow us to measure the CD8+ T-cell survival and proliferation rates in the same 
way as we did for CD4+ T-cells. We predict a similar immunosuppressive effect of IDO 
expression on the CD8+ subset of primary human T-cells, but the extent of that 
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immunosuppression can differ due to inherent differences in inter- and intracellular 
activation between these two sets of immune cells.  
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Conclusion 
Our work provides evidence for regulation of the adaptive immune response by 
vascular cells through interferon-gamma (IFN-γ)-inducible expression of indoleamine 
2,3-dioxygenase (IDO) in human vascular smooth muscle cells (VSMCs), which inhibits 
CD4+ T-cell proliferation in response to activated, allogeneic endothelial cells (ECs). 
The mechanism of inhibition is through tryptophan starvation mediated by the metabolic 
action of IDO, not by the generation or presence of toxic kynurenine metabolites. The 
depletion of tryptophan in the microenvironment suppresses CD4+ T-cell activity without 
exerting overt negative effects on IDO-expressing VSMCs due to the presence of an 
adaptive enzyme that helps VSMCs increase the efficiency of tryptophan use. IDO is 
indeed the key modulator of medial immunosuppression by VSMCs since specific 
inhibition of IDO with 1-methyl-tryptophan reverses this effect. We have proven our 
hypothesis using both in vivo and in vitro models showing a feedback loop involving 
IFN-γ and IDO mediating the immune response by vascular cells, which has further 
elucidated the inflammatory states of atherosclerosis and graft arteriosclerosis. In fact, 
these findings extend the regulatory role of IDO in adaptive immunity and further support 
its function of establishing a variety of immunoprivileged sites throughout the body to 
protect from unwanted immune responses (i.e. fetal rejection, autoimmunity, allograft 
rejection and medial inflammation). This research holds important implications in the 
future management of graft arteriosclerosis since, if we can target the immune response 
underlying the eventual failure of blood vessel grafts, we can extend the health of many 
undergoing transplant surgery. We look to target either the expression of IDO or more 
generally affect the availability of tryptophan as a method of immune regulation. 
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Figure 1. Pathway of Tryptophan Metabolism by Indoleamine 2,3-Dioxygenase. 
Tryptophan is an essential amino acid that must be obtained from dietary sources. 
Of the tryptophan that is not used for protein synthesis, 99% is metabolized by 
indoleamine 2,3-dioxygenase (IDO), which is induced by interferon-γ (IFN-γ) in most 
human cells. IDO catalyzes the first and rate-limiting step along the pathway generating 
kynurenine metabolites. Therefore, tryptophan represents a source for mainly two pivotal 
biochemical pathways: (1) the IDO-catalyzed formation of a series of biologically active 
metabolites, referred to as kynurenines, and (2) the generation of 5-hydroxytryptamine 
(serotonin, a vasoconstrictor and neurotransmitter that is also degraded by IDO). 
  40 
 
Grohmann U, Fallarino F, Puccetti P. Tolerance, DCs and tryptophan: much ado about IDO.  
Trends Immunol 2003;24:242-8.  
 
Figure 2. Multiple Roles Assigned to Indoleamine 2,3-Dioxygenase (IDO).  
(a) By controlling the metabolism of tryptophan and altering its levels within the 
local environment, indoleamine 2,3-dioxygenase (IDO) has been given a role in the 
innate immune response against a variety of pathogens. It is now clear that this same 
mechanism allows IDO to play a role in the adaptive immune system by way of T-cell 
regulation. This allows for the control of a number of cell-mediated immune responses, 
including fetal rejection, autoimmunity, and allograft rejection19, 26-28. (b) Another 
protective mechanism of IDO is the clearance of free radicals, such as superoxide anion, 
that are released during inflammatory states (e.g. infection, response to allogeneic 
antigen, etc.). (c) However, it is not clear whether the functioning of IDO in these 
instances is always beneficial to the host. By acting on a variety of indole derivatives 
other than tryptophan, IDO affects the balance of important neuroendocrine molecules, 
including tryptamine, serotonin, and melatonin. Therefore, IDO has been carefully looked 
at for its potential involvement in a number of neurological disorders83,84. (d) IDO has 
also been associated with neuroactive and neurotoxic properties due to its production of 
tryptophan breakdown products, referred to as kynurenines19, 82-84. (e) Kynurenines have 
been posited to additionally exhibit immunoactive properties and could contribute to the 
control of immune homeostasis19, 32, 33, 85. 
  41 
 
 
Quan J, Tan PH, MacDonald A, Friend PJ. Manipulation of indoleamine 2,3-dioxygenase (IDO) for clinical 
transplantation: promises and challenges. Expert Opin Biol Ther 2008;8:1705-19. 
 
Figure 3. Multiplicity of Ways in Which Indoleamine 2,3-Dioxygenase (IDO)  
Can Regulate T-cells.  
Tryptophan metabolism by indoleamine 2,3-dioxygenase (IDO) leads to 
decreased tryptophan levels and increased kynurenine metabolite levels within the local 
microenvironment surrounding IDO-expressing cells. The altered concentrations of these 
biologically active molecules can lead to a variety of immunosuppressive effects on 
human T-cells including: (1) activation and differentiation of regulatory T-cells, (2) T-
cell anergy and cell cycle arrest, (3) activation of apoptotic cascades, and (4) inhibition of 
proliferative signals, i.e. interleukin-2 (IL-2, not shown). The molecular action of 
kynurenine metabolites is yet to be elucidated, although kynurenines have been recently 
found to promote apoptosis in T-helper type 1 cells19, 85 along with inducing the 
differentiation of regulatory T-cells32, 33.  
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Figure 4. Regulatory Feedback Loop Involving Interferon-Gamma (IFN-γ) and  
Indoleamine 2,3-Dioxygenase (IDO).  
We describe how interferon-gamma (IFN-γ) expressed by activated T-cells, and 
indoleamine 2,3-dioxygenase (IDO) expressed by antigen-presenting cells (represented 
here by a dendritic cell) constitute a feedback loop for T-cell activation, differentiation, 
and regulation. This model suggests that there is a built-in check for the adaptive immune 
system in which dendritic cells (DCs), after encountering a foreign antigen, activate T-
cells that then secrete IFN-γ to act in paracrine fashion and activate IDO expression by 
the original DCs. IDO then suppresses T-cell proliferation through tryptophan 
metabolism. We extend this model to the inflammation seen in atherosclerosis and graft 
arteriosclerosis, in which vascular smooth muscle cells express IDO and therefore act as 
the principal mediator of tolerance. This concept is in line with growing evidence in the 
literature that suggests a common mechanistic basis of tolerance induction in 
transplantation, tumor surveillance, autoimmunity, and pregnancy19, 26-28.  




Figure 5. Schematic Depiction of Co-Culture and Transwell Assays. 
For co-culture experiments, endothelial cells (ECs) with or without interferon-
gamma (IFN-γ) treatment were placed into wells and co-cultured with CD4+ T-cells to 
observe the effect on CD4+ T-cell proliferation. The same was done with vascular 
smooth muscle cells (VSMCs) with or without IFN-γ treatment and CD4+ T-cells.  
In transwell assays, we took the cell co-cultures and added a variety of cell types 
on top of semi-permeable inserts in order to rule-out the effects of cell-to-cell interactions 
on CD4+ T-cell proliferation. Therefore, any observations would be attributed to local 
factors (e.g. changes in concentrations of biologically active molecules) being altered by 
cells in the top inserts. 
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Abbreviations: ECs, endothelial cells; RPMI, Roswell Park Memorial Institute (type of medium, i.e. RPMI 
1640); FBS, fetal bovine serum; TRP, tryptophan; ELISA, enzyme-linked immunosorbent assay; FACS, 
fluorescence-activated cell sorting (FACS). 
 
Figure 6. Example Design of a Co-Culture Experiment. 
All co-culture experiments were performed with unactivated (without interferon-
gamma treatment, MHC Class II negative) endothelial cells (ECs) representing negative 
controls (i.e. minimal CD4+ T-cell proliferation expected). Activated (with interferon-
gamma treatment, MHC Class II positive) ECs were used as positive controls (i.e. 
increase in CD4+ T-cell proliferation expected). Experimental conditions were altered 
according to the investigation under study (here we show the use of custom-made 
tryptophan-deficient medium supplemented with increasing concentrations of tryptophan 
to observe the effect on CD4+ T-cells co-cultured with unactivated or activated ECs, 
respectively). Duplicate samples were prepared for enzyme-linked immunosorbent assay 
(ELISA) analysis as well as for fluorescence-activated cell sorting (FACS) analysis. 
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Abbreviations: PBMC, peripheral blood mononuclear cell; α-SMA, α-smooth muscle actin; IDO, 
indoleamine 2,3-dioxygenase; x-sec, cross-section. 
Data are n=6 and *p<0.05 when comparing samples from the experimental group receiving PBMC 
reconstitution versus samples from the control group without reconstitution. 
Cuffy MC, Silverio AM, Qin L, et al. Induction of indoleamine 2,3-dioxygenase in vascular smooth muscle 
cells by interferon-gamma contributes to medial immunoprivilege. J Immunol 2007;179:5246-54.  
 
Figure 7. Medial Sparing by Allogeneic T-cells is Associated with Vascular Smooth 
Muscle Cell Expression of Indoleamine 2,3-Dioxygenase.  
(A-C) Human coronary artery grafts were analyzed by immunohistochemistry 
four weeks after placebo treatment (left column) or human allogeneic PBMC 
reconstitution (right column) of SCID/beige mouse recipients. Antibodies to (A) 
CD45RO, (B) α-SMA, and (C) IDO were used for the study. CD45RO is a protein  
  46 
Figure 7. continued 
 
phosphatase expressed on the surface of activated and memory T-cells. α-SMA is a 
specific isoform of actin that is found in vascular smooth muscle cells. IDO is an enzyme 
that catalyzes the first and rate-limiting step of tryptophan metabolism. Positive 
immunostaining is a crimson/brown color. Cross-sections of the artery grafts are shown 
using high magnification photomicrographs with black arrows marking the internal 
(above) and external (below) elastic laminae indicating the boundaries of the media. 
Addition of PBMCs serves to activate the immune response in endothelial and vascular 
smooth muscle cells. Therefore, we see T-cells infiltrating the blood vessel wall but 
sparing the medial layer (right column, A). There is no significant difference in the 
amount of vascular smooth muscle cells after activation (right column, B) since the 
medial layer is spared from immune attack. This is associated with positive IDO 
immunostaining indicating the expression of IDO by activated vascular smooth muscle 
cells (right column, C). Without activation by PBMCs, T-cells are not recruited into the 
blood vessel wall and we observe normal controls (left column, A-C). 
(D) Manual counting of CD45RO+ cells was performed and is reported for each 
layer: intimal, medial, and adventitial. The counts are normalized to the area of each 
respective layer. We demonstrate a significant difference (*p<0.05) of a 100-fold greater 
density of T-cells in the adventitia of the experimental group versus control group. There 
is also a significant difference (*p<0.05) of a 2000-fold greater density of T-cells in the 
intima of the experimental group versus control group, but no statistical significance seen 
in the medial layer.  
(E) α-SMA+ cells in the media were also counted per cross-section (x-sec) of 
human coronary artery grafts four weeks after placebo treatment (open bar) or human 
allogeneic PBMC reconstitution (solid bar) of the murine hosts. We do not see any 
significant difference in α-SMA+ cell counts since there is minimal inflammation in the 
medial layer even after activation by PBMCs.
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Abbreviations: IDO, indoleamine 2,3-dioxygenase; IFN-gamma, interferon-gamma; EC, endothelial cell; 
VSMC, vascular smooth muscle cell; GAPDH Ct, glyceraldehyde 3-phosphate dehydrogenase count. 
Data represent single values and are representative of three independent experiments. 
 
Figure 8. In Vitro Confirmation of Interferon-γ-Inducible Expression of 
Indoleamine 2,3-Dioxygenase by Vascular Smooth Muscle Cells. 
Using reverse transcription polymerase chain reaction (RT-PCR), we confirm the 
expression of IDO in activated VSMCs by showing the difference in IDO RNA levels 
between VSMCs, ECs, and CD4+ T-cells. IFN-γ treatment was performed to stimulate 
expression of IDO, and IDO transcripts were normalized to GAPDH mRNA. GAPDH is 
an enzyme that catalyzes glucose metabolism and is constitutively expressed at high 
levels in most cells. It therefore serves as a standard of measurement for specific RNA 
expression. IDO shows at most a 100-fold greater expression in vascular smooth muscle 
cells (red bars) as compared to ECs (blue bars) and CD4+ T-cells (yellow bars) after 
treatment with 100ng/mL of IFN-γ. We also show a dose-dependent response to IFN-γ.
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Abbreviations: EC, endothelial cell; VSMC, vascular smooth muscle cell; IFN-γ, interferon-gamma; TRP, 
tryptophan; KYN, kynurenine. 
Data represent single values and are representative of three independent experiments. 
Cuffy MC, Silverio AM, Qin L, et al. Induction of indoleamine 2,3-dioxygenase in vascular smooth muscle 
cells by interferon-gamma contributes to medial immunoprivilege. J Immunol 2007;179:5246-54. 
 
Figure 9. Interferon-γ Induces Indoleamine 2,3-Dioxygenase Activity in Vascular 
Smooth Muscle Cells. 
(A, B) Levels of tryptophan, (C, D) kynurenine, and (E, F) a ratio of kynurenine 
to tryptophan (log scale) were determined by high performance liquid chromatography 
(HPLC) from the supernatants of cultured endothelial cells (ECs, open bars) and vascular 
smooth muscle cells (VSMCs, solid bars) treated with IFN-γ at 30 ng/mL for various 
times (left column) or at different doses for 48 hours (right column). Greater induction of 
indoleamine 2,3-dioxygenase (IDO) expression in VSMCs versus ECs correlated with 
orders of magnitude greater IDO activity as shown by time and dose response to IFN-γ 
for tryptophan depletion, kynurenine production, and the ratio of metabolite to precursor. 
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Abbreviations: EC-, IFN-γ-untreated endothelial cell; EC+, IFN-γ-pretreated endothelial cell; VSMC-, 
IFN-γ-untreated vascular smooth muscle cell; VSMC+, IFN-γ-pretreated vascular smooth muscle cell; 
CFSE, carboxyfluorescein succinimidyl ester (fluorescent cell staining dye); IL-2, interleukin-2; TRP, 
tryptophan; KYN, kynurenine. 
Data are means±SEM; n=6 for ELISA and n=3 for HPLC; *p<0.001 all vs. EC- control, †p<0.01 VSMC+ 
vs. EC+, and §p<0.001 VSMC+ vs. VSMC-. 
Cuffy MC, Silverio AM, Qin L, et al. Induction of indoleamine 2,3-dioxygenase in vascular smooth muscle 
cells by interferon-gamma contributes to medial immunoprivilege. J Immunol 2007;179:5246-54. 
 
Figure 10. Interferon-γ-Pretreated Vascular Smooth Muscle Cells by Themselves do 
not Activate CD4+ T-cells but do Demonstrate IDO Activity. 
(A) Untreated (-) and IFN-γ-pretreated (+) endothelial cells (ECs) or vascular 
smooth muscle cells (VSMCs) were co-cultured with CFSE-labeled CD4+ T-cells. After 
nine days, the cells were labeled with CD4-PE and analyzed by flow cytometry. The 
percentage of proliferating CD4+ T-cells was calculated using counts in the gated area of 
the upper left quadrant (indicated by a red circle) compared to the total number of CD4+ 
T-cells in the sample. The left quadrant was chosen since proliferating CD4+ T-cells are 
smaller in size and therefore exhibit less CFSE and CD4-PE staining than naïve CD4+  
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T-cells. We show a difference in the ability of IFN-γ-pretreated vascular cells to activate 
allogeneic CD4+ T-cells within the co-culture system. ECs treated with IFN-γ express 
major histocompatibility complex (MHC) class II molecules, thereby enabling them to 
activate allogeneic CD4+ T-cells and generate an increase from 0.33% to 6.04% of T-
cells proliferating. VSMCs treated with IFN-γ were also found to express MHC class II 
molecules but were unable to induce CD4+ T cell proliferation, which remained low at 
0.15%.  
Supernatants were removed after two days of co-culture and analyzed for (B) IL-2 
by enzyme-linked immunosorbent assay (ELISA) and for (C) tryptophan, (D) 
kynurenine, and (E) a ratio of kynurenine to tryptophan (log scale) by high performance 
liquid chromatography (HPLC). IL-2 is a cytokine responsible for stimulating T-cell 
proliferation. IFN-γ-treated ECs, but not VSMCs or untreated ECs, stimulated IL-2 
production by CD4+ T-cells. The lack of IL-2 secretion and CD4+ T-cell proliferation by 
IFN-γ-treated VSMCs was associated with greater tryptophan depletion and kynurenine 
production than similarly treated ECs. 
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Abbreviations: EC-, IFN-γ-untreated endothelial cell; EC+, IFN-γ-pretreated endothelial cell; VSMC-, 
IFN-γ-untreated vascular smooth muscle cell; VSMC+, IFN-γ-pretreated vascular smooth muscle cell; 
CFSE, carboxyfluorescein succinimidyl ester (fluorescent cell staining dye); IL-2, interleukin-2; TRP, 
tryptophan; KYN, kynurenine. 
Data are means±SEM; n=5; *p<0.001 all vs. EC- control, †p<0.001 VSMC+ vs. EC+, and §p<0.001 
VSMC+ vs. VSMC-. 
Cuffy MC, Silverio AM, Qin L, et al. Induction of indoleamine 2,3-dioxygenase in vascular smooth muscle 
cells by interferon-gamma contributes to medial immunoprivilege. J Immunol 2007;179:5246-54. 
 
Figure 11. Interferon-γ-Treated Vascular Smooth Muscle Cells Suppress  
CD4+ T-cell Activation by Allogeneic Endothelial Cells. 
(A) Untreated (-) or IFN-γ-pretreated (+) endothelial cells (ECs) or vascular 
smooth muscle cells (VSMCs) were placed within semi-permeable membrane inserts 
overlying CFSE-labeled CD4+ T-cells co-cultured with untreated (-) or IFN-γ-pretreated 
(+) ECs. Semi-permeable membranes were used to show that it is not a cell-to-cell 
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interaction but instead a local factor that is responsible for the results observed. After 
nine days, the cells under the inserts were labeled with CD4-PE and analyzed by flow 
cytometry. The percentage of proliferating CD4+ T-cells was calculated using counts in 
the gated area of the upper left quadrant (indicated by a red circle) compared to the total 
number of CD4+ T-cells in the sample. The left quadrant was chosen since proliferating 
CD4+ T-cells are smaller in size and therefore exhibit less CFSE and CD4-PE staining 
than naïve CD4+ T-cells. (B) The data is also shown in graph form. Compared to our 
negative control of MHC class II- ECs leading to minimal proliferation (0.19%), our 
positive control of MHC class II+ ECs showed a population of proliferating CD4+ T-
cells of almost 7%. Addition of unactivated VSMCs to the top well did not have a 
significant effect on the amount of T-cell proliferation. However, adding activated 
VSMCs led to a significant drop in proliferating T-cell numbers, from 6.75% to 1.39%.  
(C) We also measured a concurrent drop in IL-2 levels from 23 to 6 pg/mL, as 
well as (D) a significant increase in the kynurenine to tryptophan ratio from 0.08 to 0.52 
after addition of IFN-γ-treated VSMCs to the top inserts. IL-2 is a cytokine responsible 
for stimulating T-cell proliferation and is expected to be increased when T-cells are 
activated for clonal expansion. IDO activity is likely responsible for the increase in 
metabolite to precursor.
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Abbreviations: PBMC, peripheral blood mononuclear cell; 1-MT, 1-methyl-tryptophan; α-SMA, α-smooth 
muscle actin; IDO, indoleamine 2,3-dioxygenase. 
Data are n=6 and p<0.01 when comparing the experimental group receiving 1-MT versus the control group 
with placebo. 
Cuffy MC, Silverio AM, Qin L, et al. Induction of indoleamine 2,3-dioxygenase in vascular smooth muscle 
cells by interferon-gamma contributes to medial immunoprivilege. J Immunol 2007;179:5246-54. 
 
Figure 12. Inhibition of Indoleamine 2,3-Dioxygenase with 1-Methyl-Tryptophan 
Increases Medial T-cell Infiltration and Vascular Smooth Muscle Cell Loss. 
(A-C) Human coronary artery grafts were analyzed by immunohistochemistry 
four weeks after PBMC reconstitution and either administration of placebo treatment (left 
column) or the IDO inhibitor, 1-MT (right column) to SCID/beige mouse recipients. 
Antibodies to (A) CD45RO, (B) α-SMA, and (C) IDO were used for the study. CD45RO 
is a protein phosphatase expressed on the surface of activated and memory T-cells. α-
SMA is a specific isoform of actin that is found in vascular smooth muscle cells 
(VSMCs). IDO is an enzyme that catalyzes the first and rate-limiting step of tryptophan 
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metabolism. Positive immunostaining is a crimson/brown color. Cross-sections of the 
artery grafts are shown using high magnification photomicrographs with black arrows 
marking the internal (above) and external (below) elastic laminae indicating the 
boundaries of the media. We prove that the observed VSMC-mediated 
immunosuppression is due mainly to the activity of IDO and not due to a combination of 
other proteins. Specifically inhibiting IDO with 1-methyl-tryptophan (1-MT) leads to an 
increase in the presence of T-cells in the medial layer (right column, A). We also see a 
significant decrease in the expression of the VSMC marker, α-SMA, indicating VSMC 
loss most likely due to the infiltration and destruction by T-cells (right column, B). The 
possibility that VSMC loss was caused by nonspecific toxic effects of 1-MT was 
eliminated since the inhibitor had no effect on the artery grafts in the absence of immune 
reconstitution with PBMCs (shown in B insets). Although the immunosuppressive 
activity of IDO was shown to be altered by 1-MT, the presence of 1-MT did not 
significantly alter IDO expression by VSMCs (right column, C).
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Abbreviations: EC-, IFN-γ-untreated endothelial cell; EC+, IFN-γ-pretreated endothelial cell; VSMC-, 
IFN-γ-untreated vascular smooth muscle cell; VSMC+, IFN-γ-pretreated vascular smooth muscle cell; 
CFSE, carboxyfluorescein succinimidyl ester (fluorescent cell staining dye); 1-MT, 1-methyl-tryptophan; 
IL-2, interleukin-2; TRP, tryptophan; KYN, kynurenine. 
Data are means±SEM; n=5 for B-D, n=8 for E; *p<0.01 all vs. EC- control, †p<0.01 VSMC+ vs. EC+, 
§p<0.01 VSMC+ vs. VSMC-, and #p<0.01 1-MT vs. vehicle. 
Cuffy MC, Silverio AM, Qin L, et al. Induction of indoleamine 2,3-dioxygenase in vascular smooth muscle 
cells by interferon-gamma contributes to medial immunoprivilege. J Immunol 2007;179:5246-54. 
 
Figure 13. Inhibition of Indoleamine 2,3-Dioxygenase with 1-Methyl-Tryptophan 
Reverses the Vascular Smooth Muscle Cell-Mediated Suppressor Activity on T-cells. 
(A) To support our in vivo findings with 1-methyl-tryptophan (1-MT), we added 
1-MT to our transwell system to show that it can reverse the immunosuppressive effect of 
activated vascular smooth muscle cells (VSMCs) by specifically targeting IDO activity. 
CFSE-labeled CD4+ T-cells were co-cultured with untreated (-) or IFN-γ-pretreated (+) 
endothelial cells (ECs) or VSMCs or both in the absence (open bars) or presence (solid  
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bars) of 1-MT. After nine days, the cells were labeled with CD4-PE and analyzed by flow 
cytometry. The percentage of proliferating CD4+ T-cells was calculated using counts in 
the gated area of the upper left quadrant (indicated by a red circle) compared to the total 
number of CD4+ T-cells in the sample. The left quadrant was chosen since proliferating 
CD4+ T-cells are smaller in size and therefore exhibit less CFSE and CD4-PE staining 
than naïve CD4+ T-cells. (B) The data is also shown in graph form. Addition of 1-MT 
alone did not affect the proliferation of CD4+ T-cells co-cultured with IFN-γ-treated, 
allogeneic ECs (8.21% vs. 8.18%, respectively). Similarly, there was no effect of 1-MT 
on T-cell proliferation when added with untreated VSMCs to CD4+ T-cells co-cultured 
with IFN-γ-treated, allogeneic ECs (shown in B only). However, addition of 1-MT with 
activated VSMCs thwarted the expected decrease in T-cell proliferation from VSMC 
expression of IDO (8.38% vs. 2.34%, respectively).  
(C) The presence of 1-MT also reversed the IFN-γ-dependent, VSMC-mediated 
inhibition of IL-2 production by CD4+ T-cells stimulated by MHC class II+ ECs, as well 
as (D) prevented the depletion of tryptophan and the production of kynurenine by 
activated VSMCs. IL-2 is a cytokine responsible for stimulating T-cell proliferation and 
is expected to be increased when T-cells are activated for clonal expansion. Inhibition of 
IDO activity with 1-MT is likely responsible for the significantly lower than expected 
ratio of metabolite to precursor. 
(E) In recent studies using the transwell system to demonstrate VSMC- and IDO-
mediated immunosuppression, tryptophan supplementation has been shown to rescue T-
cell proliferation after challenge with activated VSMCs. This gives further evidence of 
IDO utilizing tryptophan starvation as a method of immune regulation. 
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Abbreviations: EC-, IFN-γ-untreated endothelial cell; EC+, IFN-γ-pretreated endothelial cell; VSMC-, 
IFN-γ-untreated vascular smooth muscle cell; VSMC+, IFN-γ-pretreated vascular smooth muscle cell; 
CFSE, carboxyfluorescein succinimidyl ester (fluorescent cell staining dye); 1-MT, 1-methyl-tryptophan; 
FCS, fetal calf serum; TRP, tryptophan; KYN, kynurenine. 
Data are means±SEM; n=6 for ELISA and n=3 for HPLC; *p<0.001 all vs. EC- control. 
Cuffy MC, Silverio AM, Qin L, et al. Induction of indoleamine 2,3-dioxygenase in vascular smooth muscle 
cells by interferon-gamma contributes to medial immunoprivilege. J Immunol 2007;179:5246-54. 
 
Figure 14. Indoleamine 2,3-Dioxygenase Immunosuppression is Mediated by 
Tryptophan Depletion, Not by Toxic Metabolites. 
We further characterized indoleamine 2,3-dioxygenase (IDO) by showing that its 
method of immunosuppression is not by generation of toxic metabolites but by the 
depletion of tryptophan. First, it is important to demonstrate that addition of (A) 1-
methyl-tryptophan or (B) L-tryptophan cannot, by themselves, stimulate CD4+ T-cell  
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proliferation since MHC class II+ endothelial cells (ECs) are required for CD4+ T-cell 
activation. (C) In the presence of a minimal tryptophan concentration of <0.5 µmol/L, 
CD4+ T-cells could not be activated by allogeneic IFN-γ-pretreated ECs. This minimal 
tryptophan concentration represents the level of tryptophan depletion generated by IFN-γ-
pretreated VSMCs in vitro and is obtained using a custom-made tryptophan-deficient cell 
culture medium supplemented with only 0.5% fetal calf serum (FCS) instead of the usual 
10% FCS. Also with this medium, we show that supplementation with L-tryptophan 
results in a significant increase in (C) CD4+ T-cell proliferation and (D) IL-2 production 
responding in a dose-dependent fashion. IL-2 is a cytokine responsible for stimulating T-
cell proliferation and is expected to be increased when T-cells are activated for clonal 
expansion.  
(E) In contrast, addition of three-fold higher levels of kynurenine metabolites (30 
µmol/L) than that produced by IFN-γ-treated VSMCs did not significantly affect T-cell 
clonal expansion, nor did it significantly alter (F) IL-2 production.  
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Abbreviations: WRS, tryptophanyl-tRNA synthetase; IFN-gamma, interferon-gamma; EC, endothelial cell; 
VSMC, vascular smooth muscle cell; GAPDH Ct, glyceraldehyde 3-phosphate dehydrogenase count. 
Data represent single values and are representative of three independent experiments. 
 
Figure 15. Expression of Tryptophanyl-tRNA Synthetase Allows Vascular Smooth 
Muscle Cells to Adapt to Lower Levels of Tryptophan. 
To demonstrate why vascular smooth muscle cells (VSMCs) are not as 
susceptible as other cell types to low tryptophan levels, we give evidence for the 
expression of tryptophanyl-tRNA synthetase (WRS) by VSMCs as an adaptive 
mechanism. WRS is an enzyme that is essential for tryptophan incorporation into 
proteins, and RT-PCR shows a 20-fold greater expression of WRS in VSMCs as 
compared to ECs and CD4+ T-cells (9.19, 0.33, 0.84 IDO/GAPDH mRNA ratios, 
respectively). Therefore, VSMCs may adapt to lower levels of tryptophan by increasing 
the efficiency of its use.  
